Long-term use of antiplatelet drugs by patients with transient ischaemic attack

European Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2014, Pages 241-248

  Østergaard, Kamilla ^a,b   Madsen, Charlotte ^a   Liu, Marie Louise ^a   Bak, Søren ^a   Hallas, Jesper ^c   Gaist, David ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Antiplatelet drug use; Community setting; Drug adherence; Long term non persistence; Preventative medication; Transient ischaemic attack

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DATABASES, FACTUAL; DENMARK; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS;

EID: 84895074640     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1609-2     Document Type: Article

References (26)

1. Giles MF, Rothwell PM (2007) Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 6:1063-1072
2. Clark TG, Murphy MFG, Rothwell PM (2003) Long-term risks of stroke, myocardial infarction, and vascular death in low risk patients with a non-recent transient ischaemic attack. J Neurol Neurosurg Psychiatry 74:577-580
3. Referenceprogram for behandling af patienter med apopleksi og TCI (2013) Danish Stroke Society. Available at: http://www.dsfa.dk/wp-content/uploads/ REFERENCEPROGRAMFINAL20131.pdf (in Danish)
4. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC et al (2011) Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42:227-276
5. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457-507
6. Sappok T, Faustich A, Stuckert E, Kruck H, Marx P, Koennecke H-C (2001) Compliance with secondary prevention of ischemic stroke: a prospective evaluation. Stroke 32:1884-1889
7. Hamann GF, Weimar C, Glahn J et al (2003) Adherence to secondary stroke prevention strategies - results from the German Stroke Data Bank. Cerebrovasc Dis 15:282-288
8. Burke JP, Sander S, Shah H et al (2010) Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. Curr Med Res Opin 26:1023-1030
9. Palnum KH, Mehnert F, Andersen G, Ingeman A, Krog BR, Bartels PD, Johnsen SP (2012) Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: a nationwide follow-up study. Stroke 43:802-807
10. Glader E-L, Sjölander M, Eriksson M, Lundberg M (2010) Persistent use of secondary preventive drugs decline rapidly during the first 2 years after stroke. Stroke 41:397-401
11. Bushnell CD, Olson DM, Zhao X et al (2011) Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 77:1182-1190
12. Flynn RW, MacDonald TM, Murray GD, MacWalter RS, Doney AS (2012) Persistence, adherence and outcomes with antiplatelet regimens following cerebral infarction in the Tayside Stroke Cohort. Cerebrovasc Dis 33:190-197
13. Østergaard K, Hallas J, Bak S, Christensen R, Gaist D (2012) Long-term use of antiplatelet drugs by stroke patients: a follow-up study based on prescription register data. Eur J Clin Pharmacol 68:1631-1637
14. von Weitzel-Mudersbach P, Johnsen SP, Andersen G (2011) Low risk of vascular events following urgent treatment of transient ischaemic attack: the Aarhus TIA study. Eur J Neurol 18:1285-1290
15. Gaist D, Sørensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445-448
16. World Health Organization MONICA Project Principal Investigators (1988) The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease). J Clin Epidemiol 41:105-114
17. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604-607
18. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S (2007) Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369:283-292
19. WHO Collaborating Centre for Drug Statistics Methodology (2012) Guidelines for ATC classification and DDD assignment, 2013. World Health Organization, Oslo
20. Andrade SE, Kahler KH, Frech F et al (2006) Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 15:565-574
21. StataCorp (2013) Stata: release 13. Statistical software. StataCorp LP, College Station
22. Holzer K, Feurer R, Sadikovic S, Esposito L, Bockelbrink A, Sander D, Hemmer B, Poppert H (2010) Prognostic value of the ABCD2 score beyond short-term follow-up after transient ischemic attack (TIA)-a cohort study. BMC Neurol 10:50. doi: 10.1186/1471-2377-10-50
23. Statens Serum Institut. Health Data and Disease Control Data Supplies and Medicines Statistics. Satens Serum Institut, Copenhagen. Available at: www.medstat.dk/en
24. Johnsen SP, Overvad K, Sørensen HT, Tjønneland A, Husted SE (2002) Predictive value of stroke and transient ischemic attack discharge diagnoses in The Danish National Registry of Patients. J Clin Epidemiol 55:602-607
25. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T (2007) Validity of stroke diagnoses in a National Register of Patients. Neuroepidemiology 28:150-154
26. Caetano PA, Lam JMC, Morgan SG (2006) Toward a standard definition and measurement of persistence with drug therapy: examples from research on statin and antihypertensive utilization. Clin Ther 28:1411-1424